METABOLIC & GHRH RESEARCH
Tesamorelin
10 mg
Targeting the GHRH-GH-IGF-1 Axis.
Tesamorelin (TH9507) is a synthetic analogue of human growth hormone-releasing hormone (GHRH) that stimulates endogenous growth hormone release from the pituitary gland. Clinical studies in adults with HIV-associated lipodystrophy (HIV-related body fat redistribution) have demonstrated significant reductions in excess visceral abdominal fat.
A Healthier Tomorrow
Tesamorelin
10 mg
$115.00 — or Original price was: $115.00.$103.50Current price is: $103.50. / month
Ships within 1-2 Business Days
Subscribe monthly and save 10%
- Ship to Canada,USA & Mexico
- Secure Checkout
- Add to wishlist
PREMIUM QUALITY:
Pharmaceutical-grade
INDEPENDENT TESTING:
Quality verification
BATCH TRANSPARENCY:
Product information
GLOBAL ACCESS:
Canada, USA & Mexico
SUPPORTING A HEALTHIER YOU
Targeted Science. Real Human Evidence.
Tesamorelin targets the GHRH-GH-IGF-1 axis and has been studied in randomized, placebo-controlled trials in adults with HIV-associated lipodystrophy (HIV-related body fat redistribution), where it significantly reduced visceral abdominal fat by stimulating endogenous growth hormone release and increasing IGF-1 levels. While research in other primary relates to its effects on body composition in this specific clinical context.
- Studied in adults with HIV-related body fat redistribution
- Demonstrated reductions in visceral abdominal fat
- Increases endogenous GH and IGF-1 levels
- Explored for effects on waist and trunk fat measurements
- Human clinical evidence is indication-specific
KEY AREAS OF HUMAN
KEY AREAS OF HUMAN
The Science
Evidence & Mechanism
Tesamorelin (TH9507) is a synthetic 44-amino-acid analogue of human GHRH that binds to the GHRH receptor (GHRHR) on pituitary somatotroph cells, stimulating endogenous growth hormone release and increasing circulating IGF-1 levels. In adults with HIV-associated lipodystrophy, clinical trials have demonstrated significant reductions in visceral abdominal fat, with improvements in waist and trunk fat measures. Ongoing research is exploring additional metabolic effects, but its approved clinical use is specific to HIV-related lipodystrophy, and benefits in other populations have not been established.
Stimulates natural GH release (research)
May support growth, recovery and metabolism (research)
Reductions in visceral fat observed in clinical studies (research)
May influence lipid metabolism and body composition (research)
Product Information
| Product Name | Tesamorelin |
| Development Code | TH9507 |
| Molecular Weight | ~5,135.8 Da (peptide) |
| Strength | 10 mg (lyophilized) |
| Vial Size | 3 mL |
| Purity | > 99% (HPLC) |
| Product Format | Lyophilized powder |
| Storage | Store refrigerated (2°C–8°C). Protect from light and moisture. |
| Intended Use | Research use only. Not for human or veterinary use. |
Why Choose Nextgen
- Premium quality research products
- Independent laboratory testing
- Batch transparency
- Consistent quality standards
- Milligram App integration
- Dedicated customer support
FREQUENTLY ASKED QUESTIONS
Your Questions, Answered.
Find quick answers to common questions about this Product.
Tesamorelin has been studied in adults with HIV and excess abdominal fat during antiretroviral treatment. In a randomized 26-week trial, visceral fat around the organs decreased by 15.2% in the tesamorelin group and increased by 5.0% with placebo. This is evidence for a specific clinical population, rather than a general weight-loss or visible-abdominal-definition promise.
A separate randomized study in adults with HIV-related abdominal fat accumulation examined both visceral fat and liver fat. Reductions in these measured fat deposits help explain interest in tesamorelin’s metabolic effects. They do not establish treatment of every form of fatty liver or predict the same response in people without the studied condition.
Tesamorelin has direct human imaging studies of visceral fat. Classic CJC-1295 research used the long-acting DAC form and measured hormone responses, while ipamorelin’s controlled bowel-surgery trial did not establish efficacy. Sermorelin also has a distinct evidence base. A shared connection with growth hormone does not mean these compounds deliver the same clinical benefits.
Follow-up research found that visceral-fat benefits were maintained with continued clinical treatment and tended to reverse after withdrawal. The studies also monitored IGF-1 and glucose-related effects. These outcomes belong to the studied medicine and supervised population; they do not verify the safety or effectiveness of a supplier’s research vial.